VISTA, Calif., Oct. 1, 2025 /PRNewswire/ -- In a groundbreaking showcase of innovation designed to accelerate the digital transformation of…
Favorable End-of-Phase 2 meeting with U.S. FDA for [18F]FAPI-74 for GI cancers Primary and secondary endpoints met Alignment with FDA…
Copay Assistance From The Assistance Fund Now Available for Eligible People Living With B-Cell Lymphoma ORLANDO, FL / ACCESS Newswire…
MESA, ARIZONA / ACCESS Newswire / October 1, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE), an emerging developer of…
Secure, scalable, multi-cloud platform using federated learning aims to accelerate cancer discoveries and treatments SEATTLE, WASHINGTON / ACCESS Newswire /…
The approach defies the restrictive weight loss paradigm, with early results indicating increased meal tracking and member engagement1 with new…
Strategic Expansion with Leading Franchise Network Underscores Revenue Potential and Market Leadership for SteraMist iHP TechnologyFREDERICK, Md., Oct. 01, 2025…
CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of…
Dotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy Urica…
MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc.…